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Abstract
Background: Remote care services and patient empowerment have boosted mobile health (mHealth). A study of user needs
related to mHealth for pediatric cystic fibrosis (PCF) identified the set of preferred features mobile apps should support; however,
the potential use of PCF apps and their suitability to fit into PCF clinical management remains unexplored.
Objective: We examine whether PCF holds potential for the implementation of mHealth care.
Methods: The study is based on a literature review and qualitative analysis of content and was conducted in two parts: (1) we
reviewed scientific and gray literature to explore how European countries manage PCF and conducted a qualitative study of 6
PCF units and (2) we performed a systematic review of apps available in the myhealthapps.net repository searching for cystic
fibrosis (CF) management and nutrition apps, which we analyzed for characteristics, business models, number of downloads, and
usability.
Results: European CF routine care guidelines are acknowledged in most European countries, and treatments are fully covered
in almost all countries. The majority of teams in CF units are interdisciplinary. With respect to the systematic review of apps, we
reviewed 12 apps for CF management and 9 for general nutrition management in the myhealthapps.net directory. All analyzed
apps provided functionalities for recording aspects related to the disease and nutrition such as medication, meals, measurements,
reminders, and educational material. None of the apps reviewed in this study supported pancreatic enzyme replacement therapy.
CF apps proved to be less appealing and usable than nutrition apps (2.66 [SD 1.15] vs 4.01 [SD 0.90]; P<.001, z-value: –2.6).
User needs detected in previous research are partially matched by current apps for CF management.
Conclusions: The health care context for PCF is a unique opportunity for the adoption of mHealth. Well-established clinical
guidelines, heterogeneous clinical teams, and coverage by national health care systems provide a suitable scenario for the use of
mHealth solutions. However, available apps for CF self-management do not cover essential aspects such as nutrition and education.
To increase the adoption of mHealth for CF self-management, new apps should include these features.
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Introduction
Pediatric cystic fibrosis (PCF) is a childhood-onset inherited
disease characterized by progressive lung and pancreas
deterioration, leading to premature death. Estimations in the
European Union are about 30,000 cystic fibrosis (CF) patients,
with one new case per 1800 to 25,000 newborns depending on
the region [1]. CF inception is based in the mutation of a gene
encoding the CF transmembrane conductance regulator. Despite
impressive advances relating the molecular basis of CF to
organ-level disease, life expectancy and quality of life are still
limited in CF [2]. The combination of early diagnosis and early
intervention promises to slow down the progression and improve
the clinical course of the disease [3].
The primary pillars of proper CF management include a
continuum of care and treatment in which the following goals
are highlighted: (1) maintaining lung functions as near to normal
as possible by controlling respiratory infection; (2) providing
nutritional support (ie, pancreatic enzyme supplements and an
adapted and balanced diet) to achieve adequate nutritional status
and growth [4]; and (3) complication prevention, detection, and
management [5]. To achieve these goals, a multidisciplinary
team of specialized and expert health professionals is required
[6,7].
National public health systems and health insurance systems
are in charge of supporting and covering PCF patient treatments.
While the ways countries approach these costs differ
significantly [8], care services provided are similar in many
high-income countries—mainly through specialized units in
university hospitals and specialized centers in which follow-up
outpatient visits are scheduled at 2- to 3-month intervals for
physical examination and specific laboratory tests [5,8].
CF management is time-consuming and requires a
multidisciplinary approach [4]. The number and variety of
treatments patients are prescribed complicate both follow-up
and adherence [9]. Mobile technologies (eg, mobile phones,
wearable devices) provide highly scalable new approaches to
disease management [10] and have shown evidence on benefits
for health maintenance, disease management, and prevention
of complications [11]. Mobile phone use has been rapidly
increasing worldwide [12], and more than 50% of mobile phone
owners use their devices to obtain health information [13].
Research in mobile health (mHealth) has demonstrated intrinsic
motivations to facilitate mHealth adoption and perceived risks
to inhibit it [14]. In 2013, Rai et al [15] presented a framework
for evaluating drivers of mHealth implementation and found
that users (patients and doctors) were more favorable to adopting
mHealth as a complement to (not a substitute for) face-to-face
visits. This framework has been assessed more recently [16-18],
showing beneficial results when patients are supported from
the very early stages after diagnosis and treatment initiation and
when the technology achieves medical credibility. Nevertheless,
authors highlight the need for qualitative research to assess
institutional factors that would improve the acceptance of
mHealth [16-18].
With regard to CF, Hilliard et al [19] asked 16 patients to report
experiences using mobile apps and identify potential features
to support CF self-management. Participants expressed
excitement and interest in potential future mHealth apps
designed to facilitate CF management, but they also raised
concerns about usability, usefulness, and security. In our
research within the MyCyFAPP project [20] and in the context
of a user-centered design approach [21], we interviewed 74
people including persons with CF and caregivers and health
professionals with CF care expertise. This study indicated the
readiness for self-management in the CF community in countries
that provide well-functioning health services for CF care and
identified a large diversity of user requirements and a need for
personalization. In addition, we derived a set of potentially
useful features in an mHealth app for CF: educational tools,
enzyme dosage calculation, nutritional management, treatment
organization and follow-up, health diary, practical guidelines
for treatment, communication with doctors, and communication
with peers.
Several studies analyze the features of apps and their impact on
the self-management of diseases (eg, diabetes [22], multiple
sclerosis [23], cardiovascular diseases [24], and asthma [25]).
These studies identify strengths and weaknesses of current apps
and the requirements for improving the support of chronic
diseases in the mHealth paradigm. Mobile apps have the
potential to improve clinical outcomes and increase attendance
and adherence rates [11].
Therefore, given that digital tools may be helpful in the
self-management of CF [11] and considering the latest results
on the types of features that would be particularly helpful for
PCF mobile health management [21], we examined the way
forward for the implementation of mHealth care by analyzing
how European health care systems approach PCF management
and identifying the characteristics of currently available apps
for CF management. The rationale was to contribute to the
adoption of mHealth in the management of PCF by the
identification of strengths and opportunities. Our approach
addressed the self-management of PCF using mobile
technologies and targeted teenagers, young adults, and parents
of young children.
The research presented in this paper was conducted within the
context of the MyCyFAPP European Project (grant agreement
number 643806) [20]. MyCyFAPP is developing a
self-management tool for PCF patients that allows for
personalized and accurate control and monitoring of the disease.
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Health Care and App Assessment
The approach for analyzing the context of CF management
consisted of two parts connected by the research objective. In
part 1, analysis of CF care and health care systems was oriented
to discover how different European Union countries provide
overall care related to PCF. This analysis included health care
and pharmacological support to patients and families through
national health systems and health insurances. In addition, we
analyzed the organization and coverage of health care systems
in the specific domain of CF and in particular their ability to
involve mobile apps in the process of managing the disease.
The study did not focus on individual organizations but rather
took a national perspective. In part 2, analysis of available apps
in the specific context of CF in the official market stores was
conducted to understand which types of functionalities are
already provided and whether they are being used in a clinical
context.
Part 1: National Health Care Cystic Fibrosis Coverage
Analysis
The evaluation of health care services has been considered and
used in the medical literature for improving the quality of care
delivery and its efficiency [26,27]. Kerem et al [28] proposed
a set of key performance indicators based on staff, health
services, and facilities so CF centers could be compared on
annual basis.
In the proposed country-by-country analysis of health care
systems, we aimed to discover and compare how countries are
organized to provide care and support to PCF patients based on
a subset of the indicators proposed by Kerem et al [28]. We
included medical aspects such as the follow-up protocol,
newborn screening for CF, and composition of health care teams
in CF units as well as economical aspects such as the coverage
of medication costs and type of services provided to patients.
The main sources used for analysis were the European Cystic
Fibrosis Society (ECFS) Patient Registry Annual Data Report
from 2016 [29] and reports from national health care systems.
The ECFS report contains demographic and clinical data of
44,719 consenting CF patients from 89 CF units and centers in
31 countries. Criteria for selecting countries were based on the
number of registered patients and the geographical distribution
and proportion of children (patients aged younger than 18 years)
as collected in the ECFS 2016 report. This selection included
Spain, Italy, Portugal, the Netherlands, Belgium, France,
Norway, Germany, and the United Kingdom (Table 1). The
health care organization and management of PCF in these
countries were analyzed using official reports and literature.
Data were extracted using a structured script: prevalence of
PCF, protocols and guidelines for PCF management and control,
insurance model, and availability of newborn screening
programs.
Analysis of specific PCF units relied on semistructured
interviews with professionals involved in the management of
PCF who signed the informed consent from the study that was
approved by the ethical committees of the participant hospitals.
Beyond the context analysis, we aimed at discovering the
composition of the clinical teams involved in the care and
follow-up of PCF patients, the number and type of professional
roles, and the size of the population covered by each unit.
Interviews and one group discussion included pediatricians from
6 PCF units participating in the MyCyFAPP project who agreed
to participate and gave consent to the analysis and publishing
of their responses.
Table 1. Extraction of the estimated coverage, registered patients, and proportion of pediatric cystic fibrosis for the countries included in the study
[29].










aPercentage of the total estimated cystic fibrosis population covered by the study.
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Textbox 1. Observed characteristics and descriptions of information collected for each app.
• App promoters: entities that designed, developed, funded, and launched app (full name, website, reference contact information)
• Promoter types: hospitals, cystic fibrosis units, enterprises and the type (pharma, information and communications technology-based, etc),
patient associations, charities, research projects, and other types of entities or consortia
• Promoter goals: short description of the main benefits for the user and intention of the promoting entities offering the app (eg, for dissemination
purposes, to make a business out of the features offered, to help cystic fibrosis unit patients achieve self-management goals)
• Geographical reach: available languages and geographical scope in which the app would work as expected
• Business models: how promoters make the app sustainable in economic terms. This field indicated if there is any revenue model or payment for
the use of the app or if the app was financed by the entity for promotion or as a kind of free outcome for the cystic fibrosis community. If possible,
a description of the type of funding of the app was provided (eg, research funds, donations, private investment, public investment)
• Usability score: assessment of the user experience. Three human-computer interaction experts evaluated the usability of the apps. They used an
ad hoc questionnaire composed of 5 questions focusing on design, interaction, attractiveness, structure, and understandability, each of them
graded using a 5-point Likert scale in which “1” meant a low score and “5” meant a high score
• Type of language/vocabulary: identification of the context of use of each app (eg, if app was oriented to medical aspects and therefore written
in a very technical language, if app was focused on providing guidelines and used basic or plain knowledge). Target user: adult, child, or both
• Available platforms and facts: marketplace availability (Google Play for Android and App Store for iOS), number of downloads per platform
(as an estimation of use, although downloading does not represent use of the app), number of reviews (indicating the number of people who were
interested enough to make their own assessment about app), publication date of the app on each platform and last review date (to establish app
age and how often it is updated), app version currently available (to estimate evolution and releases)
Part 2: Rapid Review of Cystic Fibrosis and Nutrition
Apps
The analysis of available mobile apps had the objective of
reviewing solutions in the field of CF oriented to pediatric
patients, families, and health professionals in the management
of CF or nutrition. The rapid review considered predefined
specific criteria, and the search was done on myhealthapps.net
(MHA), the directory of health apps supported and reviewed
by patient associations and key collaborators [26]. MHA is an
indexing and searching engine for apps endorsed by patients
and consumer health forums that includes apps from trustworthy
developers. The identification of apps was done using the search
engine at the MHA portal using the following keywords: “cystic
fibrosis” and “health diary” for CF apps and “nutrition” or
“food” for nutrition apps.
The inclusion criteria for apps were defined as having a (1) title
or description referring to CF or (2) description referring to
nutrition management linked to chronic diseases. Exclusion
criteria were defined as (1) no intended use for chronic condition
management and (2) not available in official app stores or
repositories. Collected information included the (1) app creator,
(2) app purposes, (3) identified business models, and (4) other
relevant information to be considered as a reference for app
evolution, sustainability, and fit into a health care system. A
description of the characteristics collected in the study can be
found in Textbox 1.
Statistical Analysis
Data extracted from the systematic review of apps were
compared between CF and nutrition apps. The independence
of categorical variables was assessed by means of chi-square
tests (alpha=.05), and continuous variables were assessed using
the Wilcoxon Test (alpha=.05). Statistical calculations were
done using built-in functions in Matlab R2018a (The
MathWorks, Inc).
Results
Part 1: National Health Care Cystic Fibrosis Coverage
Analysis
General Findings
Routine care was homogeneous in the 9 countries included in
this review. Regular follow-ups met international guidelines,
scheduling a full assessment of PCF patients each 2 or 3 months.
Newborn screening was implemented in 8 of the 9 studied
countries. Treatments were fully covered in almost all countries.
Only Belgium and the Netherlands only partially funded
expenses related to treatment. Generally, the type of staff
involved in CF units and reference centers for CF included
pediatricians, dietitians, psychologists, and nurses, but some
units also included social workers, physical rehabilitators, and
pharmacists.
Belgium
The Belgian health care system is based on national and private
health facilities funded by a combination of social security
contributions and health insurance funds. The national health
system reimburses a large portion of medical expenses. For CF,
a full assessment every 2 to 3 months with multidisciplinary
medical care and treatment will be reimbursed. The budget is
managed by the national health system. For CF, some
medications (eg, Creon and fat-soluble vitamins) are fully
reimbursed and some medications (eg, antibiotics) are partially
reimbursed. Newborn screening for CF has not yet been
implemented in Belgium [30].
France
The French health care system is financed by the national health
insurance and national budget. Fees and insurance levels are
determined by several factors (income, consumed goods and
services). CF patients are considered disabled and are eligible
for 100% reimbursement from the national health insurance
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system. Also, parents of children with CF are granted social
rights related to the long-term care and support of the disease
in the children. Newborn screening of CF is established in
France [31].
Germany
Germany has a universal health care system funded by a
combination of statutory health insurance and private health
insurance. The system is decentralized with private practice
physicians providing ambulatory care and independent, mostly
nonprofit hospitals providing the majority of inpatient care.
Hospitals in Germany are reimbursed by health insurance
companies according to diagnosis-related groups, a flat rate
system that defines reimbursement rates depending on the
diagnosis. Newborn screening is implemented countrywide.
Follow-up of CF patients is scheduled every 3 months in
outpatient clinics with a more in-depth checkup recommended
annually [32].
Italy
The national health service in Italy is universal and free of
charge. The system is decentralized and divided into 14 local
health agencies (Azienda Sanitaria Locale). Basic medical care
(eg, general medicine, pediatric care, hospital admissions) is
fully covered by the national system but for other types of
specialized services (eg, outpatient consultations, laboratory
tests, prostheses) patients usually must pay a low-cost fee
determined by their health care region, income level, and
subscription to a private insurance.
Patients with CF are exempt from paying for follow-ups
according to a specific law (law 548/93, GU 30/12/1993, n°305).
According to this law, patients with CF must be followed up at
specialized CF centers, which provide multidisciplinary care
(including gastroenterology and pulmonology services) and
drugs at no cost for patients. Follow-up is generally scheduled
every 2 to 3 months, but the frequency of visits depends on
patient health status and can range from daily to every 6 months
[33]. A national newborn screening program is implemented;
therefore, in the great majority of the patients, first referral to
a CF center occurs very early in life, soon after diagnosis [33].
The Netherlands
The Netherlands has a dual-level health care system in which
primary and curative care (eg, general medicine, hospital
admissions) are financed by a private mandatory insurance.
These companies are obliged to provide a package with a
defined set of insured treatments. This insurance covers 41%
of all health care expenses. Secondary care (eg, long-term care,
end-of-life care) is covered by social insurance funded by a
national budget. Follow-up of CF patients is done at least every
3 months by a pulmonologist and at least once a year by the
pediatric gastroenterologist [34]. Treatments and medical
services for CF are fully covered. CF is included in the national
newborn screening program [35].
Norway
Health care in Norway is divided into 4 regional health
authorities under the responsibility of the Ministry of Health
and Care. Health care services are funded by a national budget
and partially covered by fees. There is a unique competence
center for CF—the Norwegian Resource Center for Cystic
Fibrosis (NSCF)—located in Oslo. When CF is diagnosed and
treatment initiated, all patients are treated by the NSCF. The
parents get training about nutrition, physiotherapy, and other
important topics relevant to the patient. Later on, patients are
treated by local hospitals and local physiotherapists (NSCF if
they live in the southeast region). NSCF provides training to
the persons responsible for providing health services locally.
CF patients are followed up regularly (every 1 to 3 months
depending on health status) by doctors and nutritionists at a
local hospital in the region where the patient lives. All patients
are normally followed up at NSCF once a year. Shared cost is
set for medical supervision and medication with some services
being fully covered (eg, physiotherapy). All costs related to
screening, confirmation of diagnosis, further treatment, and
travel costs to NSCF are covered by the public health insurance.
CF newborn screening is included in the national health care
system [36].
Portugal
The health care system in Portugal consists of 3 different
coexisting systems: national, professional, and private insurance.
The national system provides universal coverage and is split
into 5 regional administrations for which the national Ministry
of Health defines health policies. General patients have to pay
a fee for the medical consultation; however, CF patients are
exempt from these fees. CF patients are scheduled every 1 to 2
months depending on patient health status (it could range from
daily to every 6 months) in the CF unit, which includes
gastroenterology and pulmonology services. Follow-up includes
dietitians (with a nutritional evaluation) and nurses (for
adherence to medical therapy) [37]. All the costs related to CF
medications are supported by the national health system.
Newborn screening is implemented countrywide and includes
CF [38].
Spain
The national health system in Spain is universal and free of
charge. The national Ministry of Health coordinates the 17
regional health systems, but the regional systems are
autonomous and define their own health policies. Spain has 22
regional CF centers, which are mainly linked to university
hospitals [39]. PCF patients are followed up every 2 to 3 months
with complete assessments by pediatric pneumologists and
gastroenterologists [39]. Additional and more frequent visits
are scheduled depending on the patient’s clinical condition. An
annual in-depth evaluation is also the rule in most CF units. In
the case of PCF, the health care system covers all medical and
pharmacy costs. Medications are delivered to the patients
through the Pharmacy unit of the hospital so patients with CF
do not have any associated medication costs. Additionally, oral
nutritional supplements are provided for free at the hospitals.
In 2012, a newborn screening program was implemented in
almost all maternity wards in the country.
United Kingdom
The National Health System (NHS) in the United Kingdom is
universal and free of charge. It consists of a decentralized system
JMIR Mhealth Uhealth 2019 | vol. 7 | iss. 4 | e13362 | p. 5http://mhealth.jmir.org/2019/4/e13362/
(page number not for citation purposes)
Martinez-Millana et alJMIR MHEALTH AND UHEALTH
XSL•FO
RenderX
divided in 4 geopolitical regions. The NHS has established a
national guideline for the diagnosis, treatment, and follow-up
of CF [40] for health care professionals in primary care, health
care professionals in secondary care, providers of CF services,
and practitioners in CF. CF prescription charges have been
abolished entirely for people in Scotland, Northern Ireland, and
Wales, but in England many people with CF still have to pay
for their prescriptions. The Cystic Fibrosis Trust offers financial
support for emergency care. Finally, the United Kingdom has
deployed newborn screening countrywide [41].
Center-Level Analysis
In Multimedia Appendix 1, we show a comparison of the
specific managerial and clinical organization of 6 European CF
units that are participants in the MyCyFAPP project [20] and
gave us access to information about their institutions. Among
these centers, 4 of the 6 have a separate unit for managing PCF
patients. The median number of pediatric patients (patients aged
younger than 18 years) in CF units is 127. The center with the
highest number of children is the University Hospital of Milan
(399); the lowest is the Associação Para Investigação,
Desenvolvimento Da Faculdade De Medicina of Lisbon (60).
The main difference among centers is the composition of clinical
teams involved in PCF care and follow-up. All the interviewed
units have roles for covering gastrointestinal, pulmonary, and
nutritional aspects of the disease (adhering to current guidelines
[4]), but we observe that one (Ramon y Cajal Hospital in
Madrid) includes two endocrinologists. Two other differences
are the inclusion of social workers and psychologists at the
University Hospital of Milan, Erasmus University Medical
Center, and KU Leuven Hospital and the inclusion of a
pharmacologist at the KU Leuven Hospital.
Involved clinical staff is heterogeneous among and within
countries; differences are not only country-specific but depend
on specific constraints at a hospital/unit level, as we observe
by comparing the two units in Spain (La Fe vs Ramon y Cajal
Hospital).
Part 2: Systematic Review of Cystic Fibrosis and
Nutrition Apps
Searches in the MHA directory [42] were performed at the
beginning of the MyCyFAPP project (February 2016) and
provided more than 500 apps for CF or nutrition management.
Of the total, 450 were general purpose apps for managing
chronic conditions from which we selected the apps targeted at
nutrition and CF-specific apps based on the inclusion and
exclusion criteria. Out of them, 9 were specifically targeted at
nutrition, 4 were CF-specific games, and 12 were CF-specific
apps (Multimedia Appendix 2).
Relevant findings that summarize related aspects in CF-specific
mobile apps on the market were classified according to the data
extraction criteria (Multimedia Appendix 3). The majority of
the apps (19/21, 90%) were provided by individual developers
(small to medium enterprises, individuals). Few apps (2/21,
9%) were promoted by the pharma industry (Cf MedCare and
MedSched). One of them, oriented to patients, has very limited
features and poor design, and one, oriented to health care
professionals, has a focused content in genes and mutations.
Only two apps (2/21, 9%) were promoted by hospitals (Tools4U
and Genia), one app (1/21, 5%) by a patient association (Flower
Breath), and one implemented by the IT department of a hospital
from the NHS Tayside region (Cystic Fibrosis: A Pocket Guide).
Many of the analyzed apps focused on scientific information
and content for education. In these cases, the content was
tailored not to patients but to researchers. None of the apps
supported pancreatic enzyme replacement therapy (PERT).
Most of the analyzed CF-specific apps did not have a concrete
business model to ensure sustainability. In Table 2, we
summarize the relevant variables by comparing specific and
nonspecific CF apps. Download payment ranged from 0 to 2
Euro (US $2.26), and 2/21 apps (9%) included advertisements
as a revenue channel.
For non-CF specific apps, business models were much more
consolidated, offering coaching services related to calorie intake
and healthy nutritional habits. CF-specific apps were focused
on the management of the disease (medication and pulmonary
symptoms). All of the analyzed apps provided functionalities
for recording aspects related to the disease such as medication,
meals, and body measurements (eg, weight, forced expiration
volume). In addition, some apps provided reminders and
educational material. Only two apps provided a feature for
communication with doctors and a virtual social community to
get in touch with other patients. Nutrition apps were
characterized by providing a wide range of features tailored to
the user. Features for coaching, personalizing goals, and aspects
of food management were predominant in these apps. Only one
app was endorsed by international organizations. Most apps are
available for both Android and iOS (except for the United States
and Sweden, where only iOS versions are available).
Overall, CF apps showed different results in the observed
metrics. Reviews and downloads were lower for CF apps than
for nutrition apps, as nutrition apps were used by a wider range
of users including healthy people and patients with chronic
conditions. CF apps were less appealing and usable than
nutrition apps (2.66 [SD 1.15] versus 4.01 [SD 0.90], P<.001,
z-value: –2.6). Updates of apps did not include features for the
specific management of CF patient needs, such as nutritional
counseling, therapy advice, and health literacy.
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Table 2. Comparative analysis of available apps for cystic fibrosis management and nutrition.

















–2.6<.0014.01 (0.90)2.66 (1.15)Usability score, mean (SD)
aCF: cystic fibrosis.
bFreemium model combines free basic services and advanced payment services.
cNot applicable.
Discussion
Principal Finding 1: Homogeneity of Health Care
Systems in Pediatric Cystic Fibrosis
Routine care was quite homogeneous in Western Europe, based
on regular follow-up every 2 or 3 months with full assessment
of patients with CF. Treatments were fully covered in almost
all countries. Only Belgium and the Netherlands were partially
funding the expenses related to treatments. Only Belgium had
not established a program for newborn screening for CF. The
fact that the visits are scheduled at similar intervals does not
mean a similar care delivery, as some are more focused on
gastroenterology and nutrition and others more on pulmonology.
Principal Finding 2: Heterogeneity of Clinical Teams
in Pediatric Cystic Fibrosis
Generally, the type of staff involved in CF units includes
pediatricians for gastroenterology and pulmonology. Most of
the units also included dietitians/nutritionists and nurses. A few
units included social workers, psychologists, physical
rehabilitators, and pharmacists.
Principal Finding 3: Apps for Cystic Fibrosis Partially
Meet User Needs
Apps for CF were focused on the management of medication,
meal intake, pulmonary symptom recording, and education. Our
systematic review concludes that current CF apps only partially
meet the user needs identified by Floch et al [21], PERT
management was not featured in any of the discovered apps,
and communication with peers and doctors was implemented
only in two apps. From the promoter point of view, the presence
of the pharma industry in the app market was limited to one
company with a relatively weak presence. Many tools were
promoted by individuals and small companies without links to
health care systems or CF units. Associations of patients were
another group of entities that promoted apps, but once more,
their presence was limited and normally their operation range
was in the scope of a country or a region. Finally, the most
interesting promoting entity was a health care provider, namely
a hospital that used the app as a tool for improving care
processes for its patients, although support was still limited in
terms of available features. CF apps yielded a higher
representation in the free licensing business model, whereas
nutrition apps showed higher distribution in pay-per-use and
in-app purchase business models, although this different
behavior was not statistically significant. We evaluated the
usability of apps by means of an ad hoc questionnaire and the
analysis of three human-computer interaction experts. App
usefulness, meaning the ability of the app to cope with actual
user needs, is an important attribute but difficult to measure
without involving users. We therefore included as surrogate
parameters the number of reviews and number of downloads
as recorded in MHA at the time of the review.
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mHealth in Pediatric Cystic Fibrosis Management:
The Time Is Now
Care models in Western European countries differ slightly in
the management of CF, and some of them provide a favorable
context for support of self-management. Nutrition is a key factor
in the progression of any disease [43], and CF standards of care
guidelines recommend nutrition counseling and support at any
stage of the disease by expert dietitians [44]. The interviewed
units included nutritionist or dietitians on the clinical team,
while other disciplines (eg, social workers, psychologists,
endocrinologists) weren’t represented in all units. Mobile apps
could fill this gap by delivering psychosocial advice and
follow-up and, in parallel, offering services for multidisciplinary
control by means of distributed technology (external services
or services from other countries).
Complete patient empowerment supporting shared decision
making (ie, patient is involved in health care decision-making
processes) and self-determination (ie, patient has the power to
choose own goals) is unrealistic in the case of CF [21]. We do
not see mHealth as a unique tool for managing PCF but as a
combination of self-management and patient empowerment
with telemedicine tools for accessing medical, nutritional, and
psychological services irrespective of patient location. This
model has been already tested in other chronic diseases in
children (eg, type 1 diabetes mellitus), in which a combination
of self-reporting outcomes, communication and tools for
education, and gamification has shown positive health impact
[22]. In a recent systematic review of 23 mHealth interventions,
Marcolino et al [11] discovered that the most popular mHealth
intervention was based on strategies to promote behavior change.
In combination with our results, this shows that the potential of
mHealth in PCF needs further efforts, and apps must go beyond
offering management tools to support, educate, and motivate
patients to adopt and maintain healthier habits.
CF is a disease for which tremendous progress has been made
in the field of medical care [45] but for which costs of care are
very high and in the case of nonhospital costs can account for
up to 50% of total lifetime expenditures of the disease [46].
Children with CF are usually diagnosed in the first year of their
life [47] and subsequently need intensive support from family
and health care services. In a study on the effect of deprivation,
Taylor-Robinson et al [48] discovered that children with CF
from more disadvantaged areas had worse growth and lung
function compared with children from more affluent areas.
Disadvantaged families had a higher burden of treatment,
leading to a disruption of school and family life. In this context,
telemedicine and mHealth can ameliorate the access to health
care services and follow-up by means of remote consultation,
access to health education, and patient empowerment [49,50].
Equality in access to health care services has been recognized
as a key factor to guarantee equal medical assistance and
well-being for all European citizens [51].
The current approach for PCF management is focused on
reacting to the effect of health deterioration, focusing on the
acute phase of the disease. Democratization of technology is a
good opportunity to change the health care management model
with the essential objective of improving the quality of life by
shifting the hospital-centered approach to a patient-centered
paradigm. A better understanding of disease mechanisms and
treatment effects leads to an improvement in health outcomes
[52]. This suggests that small changes in children’s environment
can have large effects on behavior and can be used in
self-management of PCF.
The introduction of telemedicine will require changes in health
care systems and CF units, but before organizational and
cost-effectiveness studies are conducted, further research is
needed on the implementation of systems that cover specific
patient needs and engage patients and relatives to use the
technology for managing the disease.
CF apps including the features of nutrition and PERT
self-management have great potential to improve the prognosis
of the disease as nutrition is an action that occurs every day,
several times a day. If we achieve an adequate nutrient intake
and PERT dose, the nutritional status will very likely improve.
The importance of this is that nutritional status is the parameter
that most correlates with disease prognosis and survival.
Limitations
Our study has some limitations. Part 1 covered a wide proportion
of European countries, although not all of them have been
included. Data were collected with the help of the ECFS Patient
Registry [29], but data coverage is relatively low in some
countries, meaning that not everyone with CF is represented in
the data. Moreover, the study has been limited to treatment,
follow-up, and general organizational information, excluding
other interesting indicators such as costs, resources, and
macroeconomic indicators.
Our evaluation of the heterogeneity of clinical teams in PCF
has a high risk of selection bias as we only used data from 6
PCF units participating in the MyCyFAPP project. Although
the information from these units is reliable, these may not be a
representative sample of all units in Europe. In the part 2, the
systematic review consisted of queries to the MHA directory
search engine, and some apps for CF management may have
been missed because the search terms didn’t match the
description or the metadata. The unique source for the systematic
review of apps was the MHA repository [26] because it contains
apps endorsed by patient groups and trustworthy developers. A
wider search of apps may be conducted in official app stores
such as Google Play (Android) and App Store (iOS) to increase
the sample size. Finally, for the evaluation of apps we defined
a simple score to discriminate design and appeal, although a
standard quality assessment tool should be used to perform an
in-depth analysis.
Comparison With Prior Work
mHealth is a big opportunity to relieve the burden of health care
systems [12]. Apps are increasingly being used to follow
treatments, improve patient adherence [53], and provide remote
access to health services [54]. Prior research has focused on the
potential of mHealth in the self-management of diseases [23],
but the potential of mHealth to meet the existing needs of
patients using existing app functionalities should also be
considered.
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A mobile app represents a unique channel for the direct
communication between patients and doctors beyond classical
mechanisms like phone calls or emails. Health care professionals
will have to adapt their clinical protocols and internal procedures
to this new paradigm [24]. More evidence is needed on the
impact and effectiveness of integrating such tools into CF
routine care [55]. Wearable sensors and tracking systems [56]
are opportunities for the automatic collection of data by
CF-related apps, a factor that could increase their effectiveness
in follow-up, gamification, and motivation.
An explosion of health-related apps has appeared in the different
app markets in the last 5 to 7 years [11]. New apps are landing
not in an incipient research and market scenario but in a
consolidated research field and business. Apps in health should
demonstrate their effectiveness in meeting clinical and
engagement end points in the long term [57]. Multidisciplinary
research should aim at delivering tools for remote and
self-management from several perspectives, including usability
aspects, motivation factors, perceived usefulness, and economic
sustainability [58].
Conclusions
The health care context for PCF is a good opportunity for the
development of mHealth solutions. The heterogeneity of clinical
teams, coverage of national health systems, and geographical
distribution of CF units build a suitable scenario for the use of
mHealth solutions. CF apps included in our study are mainly
based on symptom recording and management of reminders for
medications and meals. mHealth features for specific nutritional
management, social support, communication with health
professionals, and decision support should be explored to
increase the adoption of apps in the management of CF.
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